The Cambridge ECMC aims to develop molecular prognostic and diagnostic tests to aid treatment decisions. The Centre focuses on genetic predisposition to cancer and the identification of high-risk groups. This is being achieved by building on local strengths in genomics, pharmacogenetics, molecular pathology, molecular imaging, clinical informatics, and computational biology.
The overall aim of the Cambridge ECMC is to deliver personalised cancer medicine as the means to better achieve cancer control. This personalisation of cancer medicine uses the detailed characterisations of both the neoplasm and of the patient to improve screening, diagnosis, targeted treatment, and treatment monitoring.
Cancer control will ultimately be achieved through prevention, through early diagnosis, through better use of currently available treatments, and through the development of new better targeted therapeutics. The Cambridge ECMC provides support related to each of these key areas.
As of the 2017-22 quinquennium the Cambridge ECMC is also a member of the Paediatric Network. Information relating specifically to the Cambridge Paediatric ECMC can be found here.
The Cambridge ECMC will focus on three strategic objectives:
Translating biological discoveries into effective new cancer therapies;
Implementing new devices and biomarkers capable of detecting cancer early and monitoring cancer progression and treatment response;
Promoting patient and public involvement in experimental cancer medicine.
In particular, the Cambridge ECMC will provide infrastructure support for six broad research areas:
Early phase clinical trials and experimental therapeutics
Tumour monitoring (advanced cancer imaging)
Tumour monitoring (liquid biopsy, cfDNA)
Translational research in late phase trials
Screening and intervention in high-risk groups
Organisations affiliated with the Cambridge ECMC:
Contact the Centre Manager: